The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Carnitine transport: Pathophysiology and metabolism of known molecular defects
Abstract
Summary: Early‐onset dilatative and/or hypertrophic cardiomyopathy with episodic hypoglycaemic coma and very low serum and tissue concentrations of carnitine should alert the clinician to the probability of the plasmalemmal high‐affinity carnitine transporter defect. The diagnosis can be established by demonstration of impaired carnitine uptake in cultured skin fibroblasts or lymphoblasts and confirmed by mutation analysis of the human OCTN2 gene in the affected child and obligate heterozygote parents. The institution of high‐dose oral carnitine supplementation reverses the pathology in this otherwise lethal autosomal recessive disease of childhood, and carnitine therapy from birth in prospectively screened siblings may altogether prevent the development of the clinical phenotype. Heterozygotes may be at risk for cardiomyopathy in later adult life, particularly in the presence of additional risk factors such as hypertension and competitive pharmacological agents. OCTN2 belongs to a family of organic cation/carnitine transporters that function primarily in the elimination of cationic drugs and other xenobiotics in kidney, intestine, liver and placenta. The high‐ and low‐affinity human carnitine transporters, OCTN2 and OCTN1, are multifunctional polyspecific organic cation transporters; therefore, defects in these transporters may have widespread implications for the absorption and/or elimination of a number of key pharmacological agents such as cephalosporins, verapamil, quinidine and valproic acid. A third organic/cation carnitine transporter with high specificity for carnitine, Octn3, has been clonedin mice. The juvenile visceral steatosis (jvs) mouse serves as an excellent clinical, biochemical and molecular model for the high‐affinity carnitine transporter OCTN2 defect and is due to a spontaneous point mutation in the murine Octn2 gene on mouse chromosome 11, which is syntenic to the human locus at 5q31 that harbours the human OCTN2 gene.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More direct evidence linking carnitine imbalance to mitochondrial dysfunction comes from the juvenile visceral steatosis (jvs) mice, a genetic model of primary carnitine deficiency.”
From Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control (2009) · cites this paper as [42]
In the citing paper
“These animals harbor a spontaneous point mutation in OCTN2, resulting in severely depleted tissue carnitine content and marked derangements in mitochondrial genesis and morphology, as well as whole body lipid and energy metabolism (41,42).”
From Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control (2009) · cites this paper as [42]
Citations
Cites
A simple method for displaying the hydropathic character of a protein
Kyte, J., & Doolittle, R. F. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90515-0 · Cited by 22,843
Walker, J. E., Saraste, M., Runswick, M. J., & Gay, N. J. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01276.x · Cited by 5,312
The P-loop — a common motif in ATP- and GTP-binding proteins
Saraste, M., Sibbald, P. R., & Wittinghofer, A. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90281-f · Cited by 2,056
Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion
den Dunnen, J. T., & Antonarakis, S. E. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<45::aid-humu10>3.0.co;2-t · Cited by 1,764
Carnitine—metabolism and functions
Bremer, J. (1983) · Physiological Reviews · doi:10.1152/physrev.1983.63.4.1420 · Cited by 1,666
Tamai, I., Ohashi, R., Nezu, J.-I., Yabuuchi, H., Oku, A., Shimane, M., Sai, Y., & Tsuji, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20378 · Cited by 697
Bieber, L. L. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.001401 · Cited by 623
McGarry, J. D., Mills, S. E., Long, C. S., & Foster, D. W. (1983) · Biochemical Journal · doi:10.1042/bj2140021 · Cited by 556
Nezu, J.-I., Tamai, I., Oku, A., Ohashi, R., Yabuuchi, H., Hashimoto, N., Nikaido, H., Sai, Y., Koizumi, A., Shoji, Y., et al. (1999) · Nature Genetics · doi:10.1038/5030 · Cited by 554
Mechanisms mediating renal secretion of organic anions and cations
Pritchard, J. B., & Miller, D. S. (1993) · Physiological Reviews · doi:10.1152/physrev.1993.73.4.765 · Cited by 490
Research works printed but not linked: 5
- De Vivo DC, 1990, Primary and secondary disorders of carnitine metabolism, Int Pediatr, 5, 134
- Hamilton JW, 1983, Studies of L‐carnitine absorption in man, Gastroeneterology, 84, 1180
- 10.1002/(SICI)1098-1004(200001)15:1<118::AID-HUMU28>3.0.CO;2-8 · DOI
- 10.1002/(SICI)1098-1004(200003)15:3<238::AID-HUMU4>3.0.CO;2-3 · DOI
- 10.1002/1098-1004(200011)16:5<401::AID-HUMU4>3.0.CO;2-J · DOI
Cited by
Stephens, F. B., Constantin‐Teodosiu, D., & Greenhaff, P. L. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2006.125799 · Cited by 396
A modern approach to the treatment of mitochondrial disease
The Mitochondrial Medicine Society, Parikh, S., Saneto, R., Falk, M. J., Anselm, I., Cohen, B. H., & Haas, R. (2009) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0046-0 · Cited by 348
Noland, R. C., Koves, T. R., Seiler, S. E., Lum, H., Lust, R. M., Ilkayeva, O., Stevens, R. D., Hegardt, F. G., & Muoio, D. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.032888 · Cited by 317
Schimpf, R., Wolpert, C., Gaïta, F., Giustetto, C., & Borggrefe, M. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.03.026 · Cited by 184
Enzymology of the carnitine biosynthesis pathway
Strijbis, K., Vaz, F. M., & Distel, B. (2010) · IUBMB Life · doi:10.1002/iub.323 · Cited by 155
Metadata
- Authors
- Tein, I.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Tein, I.
- ORCID
- Tein, I.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2003-03
- Volume
- 26
- Issue
- 2-3
- Pages
- 147-169
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W1569055531
- Cited by
- 140
- References
- 124
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 6 · 2013: 6 · 2012: 11
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Inherited Metabolic Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- carnitine transport, OCTN2, OCTN1, carnitine deficiency, cardiomyopathy, hypoglycemic coma, organic cation transporters, carnitine supplementation, autosomal recessive inheritance, drug transport, cephalosporins, verapamil, quinidine, valproic acid, genotype-phenotype correlation
- MeSH terms
- Solute Carrier Family 22 Member 5, Animals, Biological Transport, Carnitine, Carrier Proteins, Disease Models, Animal, Humans, Membrane Proteins, Mutation, Valproic Acid, Membrane Transport Proteins, Organic Cation Transport Proteins, Symporters, Mice, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carnitine transport: Pathophysiology and metabolism of known molecular defects. https://app.cochat.ai/papers/10.1023/a:1024481016187
- The paper
- Tein, I. (2003). Carnitine transport: Pathophysiology and metabolism of known molecular defects. Journal of Inherited Metabolic Disease. https://doi.org/10.1023/a%3A1024481016187
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
